Louisiana State Employees Retirement System Takes Position in Organon & Co. $OGN

Key Points

• Louisiana State Employees Retirement System opened a new position in Organon & Co., buying 115,300 shares worth about $691,000 in the first quarter.
• Institutional ownership in Organon remains high, with 77.43% of shares held by institutions and hedge funds. Several large investors, including Vanguard, State Street, and AQR, also increased their stakes recently.
• Organon reported Q1 earnings that missed estimates, posting EPS of $0.71 versus $0.83 expected and revenue of $1.46 billion versus $1.49 billion expected. Analysts currently rate the stock a “Reduce” on average, with a consensus price target of $11.40.

Louisiana State Employees Retirement System bought a new stake in Organon & Co. (NYSE:OGN - Free Report) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 115,300 shares of the company's stock, valued at approximately $691,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Vanguard Group Inc. raised its position in Organon & Co. by 2.7% in the 4th quarter. Vanguard Group Inc. now owns 36,916,382 shares of the company's stock valued at $264,690,000 after purchasing an additional 987,979 shares in the last quarter. State Street Corp raised its holdings in Organon & Co. by 2.8% in the fourth quarter. State Street Corp now owns 9,597,761 shares of the company's stock valued at $68,816,000 after acquiring an additional 262,185 shares in the last quarter. AQR Capital Management LLC grew its holdings in Organon & Co. by 105.2% during the 4th quarter. AQR Capital Management LLC now owns 8,570,958 shares of the company's stock worth $61,282,000 after acquiring an additional 4,394,814 shares in the last quarter. Private Management Group Inc. grew its holdings in Organon & Co. by 38.3% during the 4th quarter. Private Management Group Inc. now owns 4,347,073 shares of the company's stock worth $31,169,000 after acquiring an additional 1,204,979 shares in the last quarter. Finally, UBS Group AG increased its position in shares of Organon & Co. by 55.2% in the 4th quarter. UBS Group AG now owns 4,295,002 shares of the company's stock valued at $30,795,000 after purchasing an additional 1,527,492 shares during the last quarter. 77.43% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on OGN. Zacks Research raised Organon & Co. from a "strong sell" rating to a "hold" rating in a report on Tuesday, April 14th. Weiss Ratings upgraded shares of Organon & Co. from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Friday, May 15th. BNP Paribas Exane restated a "neutral" rating and issued a $14.00 price objective (up from $12.00) on shares of Organon & Co. in a research note on Wednesday, April 29th. Finally, Piper Sandler upgraded Organon & Co. from an "underweight" rating to a "neutral" rating and lifted their target price for the stock from $5.00 to $14.00 in a research report on Tuesday, April 28th. Five equities research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of "Reduce" and a consensus price target of $11.40.

Organon & Co. Stock Performance

NYSE OGN traded down $0.03 during trading hours on Tuesday, hitting $13.54. 83,226 shares of the stock were exchanged, compared to its average volume of 6,581,009. The company has a market cap of $3.55 billion, a price-to-earnings ratio of 14.56, a price-to-earnings-growth ratio of 1.25 and a beta of 1.54. The stock has a 50-day moving average of $13.37 and a 200 day moving average of $9.59. Organon & Co. has a 12-month low of $5.69 and a 12-month high of $13.60. The company has a quick ratio of 1.42, a current ratio of 1.97 and a debt-to-equity ratio of 9.47.

Organon & Co. (NYSE:OGN - Get Free Report) last issued its quarterly earnings data on Thursday, April 30th. The company reported $0.71 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.83 by ($0.12). The firm had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.49 billion. Organon & Co. had a return on equity of 99.95% and a net margin of 3.99%.The business's revenue for the quarter was down 3.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.02 earnings per share. As a group, equities research analysts forecast that Organon & Co. will post 3.23 earnings per share for the current year.

Organon & Co. Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, June 11th. Stockholders of record on Monday, May 11th were given a $0.02 dividend. The ex-dividend date was Monday, May 11th. This represents a $0.08 annualized dividend and a dividend yield of 0.6%. Organon & Co.'s dividend payout ratio is currently 8.60%.

Insider Activity at Organon & Co.

In other Organon & Co. news, SVP Lynette Holzbaur acquired 26,448 shares of the company's stock in a transaction dated Wednesday, May 6th. The stock was acquired at an average cost of $13.35 per share, with a total value of $353,080.80. Following the purchase, the senior vice president directly owned 52,851 shares in the company, valued at approximately $705,560.85. This trade represents a 100.17% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. 1.62% of the stock is owned by corporate insiders.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.